The Eversense CGM System provides continuous glucose monitoring for up to 6 months via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. If you’re on insulin, discover what Eversense can do for you.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we’re committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels.

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world.

Trying to keep your blood sugar in range can be stressful and time consuming, but thanks to the t:slim X2™ insulin pump with Control-IQ® advanced hybrid closed-loop technology, it now can be easier. Our community is raving about how the t:slim X2™ insulin pump with Control-IQ® technology does more than change routines, it changes lives!

Xeris Biopharma, the maker of Gvoke HypoPen^®, is dedicated to unlocking the potential of glucagon. We believe that easier-to-use medicines can have a profound impact on the lives of patients and their families. That is why our first products to market are liquid glucagon, but that is just the beginning. We are also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue advancements that have the potential to change lives.